Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7 Triple Negative Breast Neoplasms 2 Solid Tumors 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Metastatic Castration-Resistant Prostate Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 HER2-positive Breast Cancer 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Bevacizumab 233 Fluorouracil 219 Oxaliplatin 215 Irinotecan 215 Leucovorin 198 Capecitabine 153 Cetuximab 145 Panitumumab 70 Folfox protocol 51 regorafenib 43 Radiotherapy 38 pembrolizumab 37 IFL protocol 36 HMPL-013 36 trifluridine tipiracil drug combination 32 Nivolumab 32 Drug Therapy 26 Neoadjuvant Therapy 24 Trifluridine 18 Celecoxib 18 tislelizumab 17 XELOX 17 sintilimab 16 Trastuzumab 16 durvalumab 15 atezolizumab 15 aflibercept 15 Chemotherapy, Adjuvant 15 apatinib 14 Gemcitabine 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × inavolisib × Clear all

NCT07323576 2026-02-09

INAVO-CRC

Hoffmann-La Roche

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡